ENFUVIRTIDE

Search structure
Trade Names:
Synonyms:
T20
Status: Approved (2003)
Entry Type: Protein
Molecule Category: UNKNOWN
ATC: J05AX07
UNII: 19OWO1T3ZE

Structure
InChI Key PEASPLKKXBYDKL-FXEVSJAOSA-N
Smile CC[C@H](C)[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(C)=O)[C@@H](C)O)[C@@H](C)CC)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](Cc1ccccc1)C(N)=O
InChI
InChI=1S/C204H301N51O64/c1-20-102(15)166(253-195(310)137(75-100(11)12)239-200(315)150(93-258)251-190(305)143(82-112-90-215-95-219-112)248-203(318)167(103(16)21-2)254-196(311)138(76-101(13)14)240-201(316)151(94-259)252-204(319)168(105(18)260)255-197(312)139(221-106(19)261)78-108-45-47-113(262)48-46-108)202(317)233-131(58-68-164(280)281)178(293)228-130(57-67-163(278)279)182(297)250-149(92-257)198(313)232-125(52-62-155(210)266)179(294)245-145(84-157(212)268)191(306)229-124(51-61-154(209)265)175(290)224-122(49-59-152(207)263)173(288)226-126(53-63-159(270)271)176(291)222-120(43-31-33-69-205)172(287)244-144(83-156(211)267)192(307)231-127(54-64-160(272)273)177(292)225-123(50-60-153(208)264)174(289)227-128(55-65-161(274)275)180(295)235-134(72-97(5)6)185(300)237-133(71-96(3)4)184(299)230-129(56-66-162(276)277)181(296)236-135(73-98(7)8)187(302)247-147(86-165(282)283)194(309)223-121(44-32-34-70-206)171(286)241-140(79-109-87-216-117-40-28-25-37-114(109)117)183(298)220-104(17)170(285)249-148(91-256)199(314)238-136(74-99(9)10)186(301)242-142(81-111-89-218-119-42-30-27-39-116(111)119)189(304)246-146(85-158(213)269)193(308)243-141(80-110-88-217-118-41-29-26-38-115(110)118)188(303)234-132(169(214)284)77-107-35-23-22-24-36-107/h22-30,35-42,45-48,87-90,95-105,120-151,166-168,216-218,256-260,262H,20-21,31-34,43-44,49-86,91-94,205-206H2,1-19H3,(H2,207,263)(H2,208,264)(H2,209,265)(H2,210,266)(H2,211,267)(H2,212,268)(H2,213,269)(H2,214,284)(H,215,219)(H,220,298)(H,221,261)(H,222,291)(H,223,309)(H,224,290)(H,225,292)(H,226,288)(H,227,289)(H,228,293)(H,229,306)(H,230,299)(H,231,307)(H,232,313)(H,233,317)(H,234,303)(H,235,295)(H,236,296)(H,237,300)(H,238,314)(H,239,315)(H,240,316)(H,241,286)(H,242,301)(H,243,308)(H,244,287)(H,245,294)(H,246,304)(H,247,302)(H,248,318)(H,249,285)(H,250,297)(H,251,305)(H,252,319)(H,253,310)(H,254,311)(H,255,312)(H,270,271)(H,272,273)(H,274,275)(H,276,277)(H,278,279)(H,280,281)(H,282,283)/t102-,103-,104-,105+,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,138-,139-,140-,141-,142-,143-,144-,145-,146-,147-,148-,149-,150-,151-,166-,167-,168-/m0/s1

Physicochemical Descriptors

Property Name Value
Molecular Formula C204H301N51O64
Molecular Weight 4491.94
AlogP None
Hydrogen Bond Acceptor None
Hydrogen Bond Donor None
Number of Rotational Bond None
Polar Surface Area None
Molecular species None
Aromatic Rings None
Heavy Atoms None

Pharmacology

Action Mechanism of Action Reference
INHIBITOR Transmembrane glycoprotein gp41 inhibitor DailyMed
Targets EC50(nM) IC50(nM) Kd(nM) Ki(nM) Inhibition(%)
Unclassified protein
10-542 - 182 - -

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Acquired Immunodeficiency Syndrome 3 D000163 ClinicalTrials

Related Entries

Scaffolds

Side Effects from Label

Side effects Relative Frequency (%) Labels
General disorders and administration site conditions Discomfort 96.0
General disorders and administration site conditions Pain 96.0
General disorders and administration site conditions Discomfort 95.0
General disorders and administration site conditions Pain 95.0
Skin and subcutaneous tissue disorders Erythema 91.0
General disorders and administration site conditions Induration 90.0
Skin and subcutaneous tissue disorders Erythema 89.0
General disorders and administration site conditions Induration 89.0
General disorders and administration site conditions Cyst 80.0
General disorders and administration site conditions Nodule 80.0
General disorders and administration site conditions Cyst 76.0
General disorders and administration site conditions Nodule 76.0
Skin and subcutaneous tissue disorders Pruritus 65.0
Skin and subcutaneous tissue disorders Pruritus 62.0
Blood and lymphatic system disorders Ecchymosis 52.0
Blood and lymphatic system disorders Ecchymosis 48.0
General disorders and administration site conditions Induration 41.0
Gastrointestinal disorders Diarrhoea 33.5
Gastrointestinal disorders Diarrhoea 26.8
General disorders and administration site conditions Cyst 26.0
General disorders and administration site conditions Nodule 26.0
Gastrointestinal disorders Nausea 23.7
Skin and subcutaneous tissue disorders Erythema 22.0
Gastrointestinal disorders Nausea 20.1
General disorders and administration site conditions Asthenia 17.4
General disorders and administration site conditions Fatigue 17.4
General disorders and administration site conditions Asthenia 16.1
General disorders and administration site conditions Fatigue 16.1
General disorders and administration site conditions Induration 16.0
Nervous system disorders Neuropathy peripheral 15.4
Nervous system disorders Neuropathy peripheral 13.6
Investigations Weight decreased 11.1
General disorders and administration site conditions Discomfort 11.0
General disorders and administration site conditions Pain 11.0
Investigations Weight decreased 10.5
Skin and subcutaneous tissue disorders Erythema 10.0
Infections and infestations Sinusitis 9.5
General disorders and administration site conditions Discomfort 9.0
General disorders and administration site conditions Pain 9.0
General disorders and administration site conditions Decreased appetite 8.6
Blood and lymphatic system disorders Ecchymosis 8.0
Investigations Weight decreased 7.9
Psychiatric disorders Anxiety 7.5
Infections and infestations Sinusitis 7.2
Musculoskeletal and connective tissue disorders Musculoskeletal discomfort 7.0
Musculoskeletal and connective tissue disorders Myalgia 7.0
Psychiatric disorders Anxiety 6.8
Infections and infestations Skin papilloma 6.6
Investigations Weight decreased 6.6
Infections and infestations Influenza 6.5
Infections and infestations Influenza 6.2
Infections and infestations Sinusitis 6.2
Investigations Weight decreased 6.2
Infections and infestations Sinusitis 6.0
Blood and lymphatic system disorders Lymphadenopathy 5.9
Musculoskeletal and connective tissue disorders Musculoskeletal discomfort 5.6
Musculoskeletal and connective tissue disorders Myalgia 5.6
Skin and subcutaneous tissue disorders Dry skin 5.0
Blood and lymphatic system disorders Ecchymosis 5.0
General disorders and administration site conditions Decreased appetite 4.9
Infections and infestations Sinusitis 4.9
Gastrointestinal disorders Abdominal pain 4.7
Respiratory, thoracic and mediastinal disorders Cough 4.7
Gastrointestinal disorders Gastrointestinal pain 4.7
General disorders and administration site conditions Influenza like illness 4.5
Skin and subcutaneous tissue disorders Dry skin 4.3
Eye disorders Conjunctivitis 4.1
Infections and infestations Herpes simplex 4.1
Skin and subcutaneous tissue disorders Pruritus 4.0
Gastrointestinal disorders Abdominal pain 3.9
Respiratory, thoracic and mediastinal disorders Cough 3.9
Gastrointestinal disorders Gastrointestinal pain 3.9
Infections and infestations Pneumonia 3.9
General disorders and administration site conditions Decreased appetite 3.8
Gastrointestinal disorders Abdominal pain 3.7
Gastrointestinal disorders Gastrointestinal pain 3.7
Infections and infestations Herpes simplex 3.7
General disorders and administration site conditions Influenza like illness 3.7
Gastrointestinal disorders Pancreatitis 3.6
Ear and labyrinth disorders Vertigo 3.6
Infections and infestations Herpes simplex 3.5
Musculoskeletal and connective tissue disorders Pain in extremity 3.4
General disorders and administration site conditions Decreased appetite 3.2
Musculoskeletal and connective tissue disorders Musculoskeletal discomfort 3.2
Musculoskeletal and connective tissue disorders Myalgia 3.2
Infections and infestations Pneumonia 3.2
General disorders and administration site conditions Decreased appetite 3.1
Respiratory, thoracic and mediastinal disorders Nasal congestion 3.1
Musculoskeletal and connective tissue disorders Pain in extremity 3.1
Infections and infestations Skin papilloma 3.1
Gastrointestinal disorders Pancreatitis 3.0
Skin and subcutaneous tissue disorders Pruritus 3.0
Investigations Blood triglycerides increased 2.9
Infections and infestations Folliculitis 2.9
Nervous system disorders Hypoaesthesia 2.9
General disorders and administration site conditions Influenza like illness 2.9
Musculoskeletal and connective tissue disorders Pain in extremity 2.9
General disorders and administration site conditions Asthenia 2.7
General disorders and administration site conditions Decreased appetite 2.7
Gastrointestinal disorders Gastrooesophageal reflux disease 2.7
Musculoskeletal and connective tissue disorders Musculoskeletal discomfort 2.7
Musculoskeletal and connective tissue disorders Myalgia 2.7
Infections and infestations Pneumonia 2.7
Eye disorders Conjunctivitis 2.5
Respiratory, thoracic and mediastinal disorders Cough 2.5
General disorders and administration site conditions Decreased appetite 2.5
Gastrointestinal disorders Dry mouth 2.5
Infections and infestations Folliculitis 2.5
Gastrointestinal disorders Gastrooesophageal reflux disease 2.5
Respiratory, thoracic and mediastinal disorders Nasal congestion 2.5
Gastrointestinal disorders Pancreatitis 2.5
Infections and infestations Folliculitis 2.4
General disorders and administration site conditions Influenza like illness 2.4
Eye disorders Conjunctivitis 2.3
General disorders and administration site conditions Decreased appetite 2.3
Nervous system disorders Disturbance in attention 2.3
General disorders and administration site conditions Irritability 2.3
Renal and urinary disorders Nephrolithiasis 2.3
Psychiatric disorders Nightmare 2.3
Skin and subcutaneous tissue disorders Seborrhoeic dermatitis 2.3
Infections and infestations Ear infection 2.2
Skin and subcutaneous tissue disorders Erythema 2.2
Renal and urinary disorders Haematuria 2.2
Nervous system disorders Tremor 2.2
Gastrointestinal disorders Dry mouth 2.1
Skin and subcutaneous tissue disorders Acne 2.0
Investigations Blood triglycerides increased 2.0
Eye disorders Conjunctivitis 2.0
Endocrine disorders Diabetes mellitus 2.0
Metabolism and nutrition disorders Hypertriglyceridaemia 2.0
Investigations Blood triglycerides increased 1.9
Eye disorders Conjunctivitis 1.9
General disorders and administration site conditions Decreased appetite 1.9
Nervous system disorders Disturbance in attention 1.9
Gastrointestinal disorders Dry mouth 1.9
Renal and urinary disorders Haematuria 1.9
Metabolism and nutrition disorders Hypertriglyceridaemia 1.9
Nervous system disorders Hypoaesthesia 1.9
General disorders and administration site conditions Influenza like illness 1.9
General disorders and administration site conditions Irritability 1.9
Skin and subcutaneous tissue disorders Seborrhoeic dermatitis 1.9
Nervous system disorders Tremor 1.9
Infections and infestations Ear infection 1.2
Skin and subcutaneous tissue disorders Erythema 1.2
Blood and lymphatic system disorders Lymphadenopathy 1.2
Musculoskeletal and connective tissue disorders Musculoskeletal discomfort 1.2
Musculoskeletal and connective tissue disorders Myalgia 1.2
Renal and urinary disorders Nephrolithiasis 1.2
Psychiatric disorders Nightmare 1.2
Skin and subcutaneous tissue disorders Acne 0.6
General disorders and administration site conditions Asthenia 0.6
Endocrine disorders Diabetes mellitus 0.6
Infections and infestations Pneumonia 0.6
Ear and labyrinth disorders Vertigo 0.6

Adverse Reactions

SOC By Demographic Distribution
System Organ Classification (SOC)
Relative Frequency (%)
General disorders and administration site conditions
26.06
Injury, poisoning and procedural complications
21.21
Skin and subcutaneous tissue disorders
8.36
Nervous system disorders
4.93
Product issues
3.79
Infections and infestations
3.7
Metabolism and nutrition disorders
3.26
Eye disorders
3.08
Vascular disorders
2.99
Gastrointestinal disorders
2.82
Immune system disorders
2.64
Respiratory, thoracic and mediastinal disorders
2.29
Musculoskeletal and connective tissue disorders
2.11

Cross References

Resources Reference
CAS NUMBER 159519-65-0
ChEMBL CHEMBL525076
FDA SRS 19OWO1T3ZE
CONTENTS